BACKGROUND: Bronchial thermoplasty (BT) is a recently developed treatment for @entity1 with moderate-to-severe @entity565 . A few studies have suggested the clinical efficacy of this intervention. However, no study has evaluated the cost-effectiveness of BT compared to other alternative treatments for moderate-to-severe @entity56 , which currently include omalizumab and standard therapy. OBJECTIVE: To evaluate the cost-effectiveness of standard therapy, BT, and omalizumab for moderate-to-severe @entity56 in the USA. METHODS: A probabilistic Markov model with weekly cycles was developed to reflect the course of @entity565 progression over a 5-year time horizon. The study population was adults with moderate-to-severe @entity56 whose @entity565 remained uncontrolled despite using high-dose inhaled corticosteroids (ICS, with or without long-acting beta-agonists [LABA]). A perspective of the health-care system was adopted with @entity565 -related costs as well as quality-adjusted life years (QALYs) and exacerbations as the outcomes. RESULTS: For standard therapy, BT, and omalizumab, the discounted 5-year costs and QALYs were  15,400 and 3.08,  28,100 and 3.24, and  117,000 and 3.26, respectively. The incremental cost-effectiveness ratio (ICER) of BT versus standard therapy and omalizumab versus BT was  78,700/QALY and  3.86 million/QALY, respectively. At the willingness-to-pay (WTP) of  50,000/QALY and  100,000/QALY, the probability of BT being cost-effective was 9%, and 67%, respectively. The corresponding expected value of perfect information (EVPI) was  155 and  1,530 per individual at these thresholds. In sensitivity analyses, increasing the costs of BT from  14,900 to  30,000 increased its ICER relative to standard therapy to  178,000/QALY, and decreased the ICER of omalizumab relative to BT to  3.06 million/QALY. Reducing the costs of omalizumab by 25% decreased its ICER relative to BT by 29%. CONCLUSIONS: Based on the available evidence, our study suggests that there is more than 60% chance that BT becomes cost-effective relative to omalizumab and standard therapy at the WTP of  100,000/QALY in @entity1 with moderate-to-severe @entity56 . However, there is a substantial uncertainty in the underlying evidence, indicating the need for future research towards reducing such uncertainty.

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic asthma']
@entity56 :: (MESH:D004342,Disease) :: ['Allergic Asthma']
